V Alt1, A Eicher, A Bitschnau, R Schnettler. 1. Klinik und Poliklinik für Unfallchirurgie Giessen, Universitätsklinikum Giessen-Marburg, Rudolf-Buchheim-Strasse 7, 35385 Giessen. Volker.Alt@chiru.med.uni-giessen.de
Abstract
BACKGROUND AND PURPOSE: The purpose of the current study was to evaluate savings from the use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in open tibia fractures by faster fracture healing and reduction of secondary treatment costs from a health insurance perspective for Germany and to compare them to the upfront price of 2900 EUR of rhBMP-2. METHODS: Raw data from a previously published study (BESTT study) were used to conduct an economic calculation for secondary treatment costs for each patient from the standard care group and the 1.5 mg/ml rhBMP-2 group based on G-DRG 2005 prices from a health insurer's perspective for an observation period of 1 year for Germany. RESULTS: The use of rhBMP-2 leads to savings of 5697 EUR and 3183 EUR per patient for Gustilo-Anderson grade IIIB and all grade IIIA and B injuries, respectively. These savings offset the upfront price of 2900 EUR of rhBMP-2 and, therefore, net savings of 2797 EUR and 283 EUR for grade IIIB and all grade IIIA and B injuries can be achieved, respectively. These savings are mainly due to reduced sickness payments because of faster fracture healing in the rhBMP-2 group. CONCLUSIONS: The current study shows that the use of rhBMP-2 in Gustilo-Anderson grade IIIA and B open fractures leads--besides the better medical outcome for patients as shown previously in the BESTT study--to net savings from a health insurer's perspective.
BACKGROUND AND PURPOSE: The purpose of the current study was to evaluate savings from the use of recombinant humanbone morphogenetic protein-2 (rhBMP-2) in open tibia fractures by faster fracture healing and reduction of secondary treatment costs from a health insurance perspective for Germany and to compare them to the upfront price of 2900 EUR of rhBMP-2. METHODS: Raw data from a previously published study (BESTT study) were used to conduct an economic calculation for secondary treatment costs for each patient from the standard care group and the 1.5 mg/ml rhBMP-2 group based on G-DRG 2005 prices from a health insurer's perspective for an observation period of 1 year for Germany. RESULTS: The use of rhBMP-2 leads to savings of 5697 EUR and 3183 EUR per patient for Gustilo-Anderson grade IIIB and all grade IIIA and B injuries, respectively. These savings offset the upfront price of 2900 EUR of rhBMP-2 and, therefore, net savings of 2797 EUR and 283 EUR for grade IIIB and all grade IIIA and B injuries can be achieved, respectively. These savings are mainly due to reduced sickness payments because of faster fracture healing in the rhBMP-2 group. CONCLUSIONS: The current study shows that the use of rhBMP-2 in Gustilo-Anderson grade IIIA and B open fractures leads--besides the better medical outcome for patients as shown previously in the BESTT study--to net savings from a health insurer's perspective.
Authors: Shunmugam Govender; Cristina Csimma; Harry K Genant; Alexandre Valentin-Opran; Yehuda Amit; Ron Arbel; Hannu Aro; Dan Atar; Michael Bishay; Martin G Börner; Philippe Chiron; Peter Choong; John Cinats; Brett Courtenay; Robert Feibel; Bernard Geulette; Charles Gravel; Norbert Haas; M Raschke; Eric Hammacher; D van der Velde; Philippe Hardy; Michael Holt; Christof Josten; Rupert Ludwig Ketterl; Bennie Lindeque; Günter Lob; Henry Mathevon; Gerald McCoy; D Marsh; Russell Miller; Everard Munting; Stein Oevre; L Nordsletten; Amratlal Patel; Anthony Pohl; William Rennie; Peter Reynders; Pol Maria Rommens; Jean Rondia; Willem C Rossouw; P J Daneel; Stephen Ruff; Axel Rüter; Seppo Santavirta; Thomas A Schildhauer; C Gekle; Reinhard Schnettler; David Segal; Hanns Seiler; Robert B Snowdowne; Jouwert Stapert; Gilbert Taglang; Rene Verdonk; Lucas Vogels; Arnulf Weckbach; Andreas Wentzensen; Tadeusz Wisniewski Journal: J Bone Joint Surg Am Date: 2002-12 Impact factor: 5.284
Authors: David W Polly; Stacey J Ackerman; Christopher I Shaffrey; James W Ogilvie; Jeffrey C Wang; Susan W Stralka; Michael S Mafilios; Stephen E Heim; Harvinder S Sandhu Journal: Orthopedics Date: 2003-10 Impact factor: 1.390
Authors: Kimberly R Garrison; Ian Shemilt; Simon Donell; Jonathan J Ryder; Miranda Mugford; Ian Harvey; Fujian Song; Volker Alt Journal: Cochrane Database Syst Rev Date: 2010-06-16